The CIBBIM- Nanomedicine Drug Delivery and Targeting research group, led by Dr. Simó Schwartz at Vall d’Hebron Institute of Research (VHIR), has participated in a new method to prepare nanovesicles, led by doctors Jaume Veciana and Nora Ventosa, from the "http://icmab.es/biomaterials-and-materials-for-drug-delivery-therapy-diagnostics-and-sensing/1369-multifunctional-nanovesicle-bioactive-conjugates-prepared-by-a-one-step-scalable-method-using-co2-expanded-solvents" Institute of Materials Science of Barcelona (ICMAB-CSIC).The study, published in "http://pubs.acs.org/doi/abs/10.1021/nl4017072" Nanno Letters, presents a simple one-step methodology based on the use of CO2-expanded solvents to prepare multifunctional nanovesicle-bioactive conjugates. The simplicity, reproducibility, and scalability render this methodology ideal for the rapid and low-cost translation of nanomedicine candidates to the clinical practice. VHIR researchers carried out the toxicity and biocompatibility trials of this study funded by Fundació Marató de TV3. The project, called " "http://www.nanofabry.cat/" Development of nanomedicine for enzymatic replacement therapy in Fabry disease", is coordinated by Dr. Schwartz and includes the participation of researchers from ICMAB-CSIC, the Institute of Biotechnology and Biomedicine, the Barcelona Science Park, the Institute for Bioengineering of Catalonia, the Institute of Photonic Sciences and Sant Pau Hospital. Fabry disease is an X-chromosome linked disease caused by a deficiency in the lysosomal enzyme alpha-galactoside A. Without treatment, patients die before 45 years.